Jeffrey Bennett
Concepts (554)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 87 | 2026 | 139 | 19.300 |
Why?
| | Aquaporin 4 | 58 | 2026 | 101 | 8.860 |
Why?
| | Multiple Sclerosis | 34 | 2025 | 468 | 5.840 |
Why?
| | Autoantibodies | 51 | 2025 | 1470 | 5.080 |
Why?
| | Immunoglobulin G | 52 | 2024 | 900 | 4.400 |
Why?
| | Optic Neuritis | 15 | 2023 | 46 | 4.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 21 | 2026 | 852 | 2.750 |
Why?
| | B-Lymphocytes | 16 | 2024 | 858 | 2.260 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 17 | 2024 | 53 | 1.730 |
Why?
| | Optic Nerve | 12 | 2023 | 66 | 1.620 |
Why?
| | Immunologic Factors | 6 | 2025 | 248 | 1.530 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 47 | 1.510 |
Why?
| | Remyelination | 2 | 2025 | 15 | 1.490 |
Why?
| | Astrocytes | 15 | 2025 | 217 | 1.460 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 28 | 1.360 |
Why?
| | Complement Inactivating Agents | 3 | 2026 | 66 | 1.140 |
Why?
| | Neuroglia | 5 | 2024 | 173 | 1.020 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 85 | 1.000 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1448 | 0.980 |
Why?
| | Tomography, Optical Coherence | 7 | 2023 | 257 | 0.970 |
Why?
| | Complement C5 | 1 | 2025 | 80 | 0.920 |
Why?
| | Humans | 149 | 2026 | 141187 | 0.910 |
Why?
| | Magnetic Resonance Imaging | 15 | 2025 | 3709 | 0.890 |
Why?
| | Macaca mulatta | 8 | 2024 | 189 | 0.880 |
Why?
| | Epitopes | 8 | 2025 | 477 | 0.870 |
Why?
| | Cerebellum | 4 | 2025 | 218 | 0.850 |
Why?
| | Retinal Degeneration | 2 | 2023 | 39 | 0.840 |
Why?
| | Brain | 12 | 2024 | 2858 | 0.820 |
Why?
| | Natalizumab | 4 | 2020 | 40 | 0.810 |
Why?
| | Complement System Proteins | 7 | 2019 | 333 | 0.810 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 4 | 2023 | 68 | 0.800 |
Why?
| | Methylprednisolone | 1 | 2023 | 64 | 0.790 |
Why?
| | Animals | 65 | 2025 | 37657 | 0.770 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 31 | 0.760 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 854 | 0.740 |
Why?
| | Disease Models, Animal | 16 | 2025 | 4404 | 0.720 |
Why?
| | Blood-Brain Barrier | 5 | 2022 | 144 | 0.720 |
Why?
| | Autoimmunity | 4 | 2017 | 908 | 0.710 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 85 | 0.710 |
Why?
| | Myelin Sheath | 7 | 2025 | 165 | 0.690 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 43 | 0.660 |
Why?
| | Immunotherapy | 4 | 2020 | 640 | 0.650 |
Why?
| | Adult | 46 | 2026 | 39177 | 0.620 |
Why?
| | Complement C1q | 1 | 2019 | 38 | 0.600 |
Why?
| | Complement Activation | 4 | 2022 | 415 | 0.600 |
Why?
| | Plasma Cells | 7 | 2017 | 74 | 0.600 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 20 | 0.600 |
Why?
| | Middle Aged | 43 | 2026 | 34434 | 0.590 |
Why?
| | Glial Fibrillary Acidic Protein | 5 | 2024 | 112 | 0.590 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 30 | 0.590 |
Why?
| | Cell Membrane | 3 | 2017 | 724 | 0.580 |
Why?
| | Inflammation | 11 | 2023 | 2890 | 0.580 |
Why?
| | Aminopyridines | 1 | 2019 | 104 | 0.580 |
Why?
| | Papilledema | 4 | 2023 | 42 | 0.570 |
Why?
| | Central Nervous System | 5 | 2023 | 265 | 0.570 |
Why?
| | Mice | 32 | 2025 | 18048 | 0.560 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 79 | 0.560 |
Why?
| | Pyrroles | 1 | 2019 | 210 | 0.560 |
Why?
| | Female | 66 | 2026 | 75515 | 0.550 |
Why?
| | Double-Blind Method | 10 | 2025 | 1983 | 0.550 |
Why?
| | Organic Chemicals | 1 | 2019 | 127 | 0.550 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 336 | 0.550 |
Why?
| | Glucocorticoids | 2 | 2019 | 533 | 0.540 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 50 | 0.540 |
Why?
| | Microglia | 2 | 2019 | 255 | 0.530 |
Why?
| | Registries | 1 | 2025 | 2135 | 0.520 |
Why?
| | CHO Cells | 8 | 2019 | 168 | 0.520 |
Why?
| | Disease Management | 2 | 2018 | 633 | 0.520 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.520 |
Why?
| | Biomarkers | 13 | 2025 | 4174 | 0.510 |
Why?
| | Spinal Cord | 8 | 2023 | 373 | 0.510 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 142 | 0.500 |
Why?
| | Antigens, CD19 | 5 | 2022 | 133 | 0.500 |
Why?
| | Cricetulus | 7 | 2019 | 111 | 0.500 |
Why?
| | Retina | 5 | 2023 | 314 | 0.500 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1357 | 0.490 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 50 | 0.490 |
Why?
| | Mutagenesis | 2 | 2019 | 182 | 0.470 |
Why?
| | Male | 51 | 2026 | 69783 | 0.450 |
Why?
| | Stents | 2 | 2016 | 529 | 0.450 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 165 | 0.430 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 48 | 0.430 |
Why?
| | Oligodendroglia | 4 | 2025 | 179 | 0.430 |
Why?
| | Optic Atrophy | 2 | 2011 | 8 | 0.420 |
Why?
| | Temporal Arteries | 4 | 2015 | 44 | 0.420 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 155 | 0.420 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 5887 | 0.420 |
Why?
| | Intracranial Hypotension | 2 | 2025 | 58 | 0.410 |
Why?
| | Peptide Fragments | 4 | 2023 | 698 | 0.390 |
Why?
| | Antigens, Viral | 3 | 2015 | 179 | 0.390 |
Why?
| | Flow Cytometry | 9 | 2023 | 1197 | 0.380 |
Why?
| | Axons | 2 | 2022 | 198 | 0.370 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 44 | 0.370 |
Why?
| | Visual Acuity | 6 | 2021 | 443 | 0.370 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 4 | 0.360 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 116 | 0.360 |
Why?
| | Autoantigens | 5 | 2025 | 422 | 0.360 |
Why?
| | Aged | 24 | 2026 | 24574 | 0.360 |
Why?
| | Hemodynamics | 1 | 2016 | 1100 | 0.350 |
Why?
| | Recurrence | 7 | 2023 | 1110 | 0.350 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 35 | 0.350 |
Why?
| | Cricetinae | 6 | 2019 | 301 | 0.350 |
Why?
| | Gene Targeting | 1 | 2011 | 83 | 0.350 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 157 | 0.350 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 98 | 0.340 |
Why?
| | Nerve Degeneration | 1 | 2010 | 49 | 0.340 |
Why?
| | Stilbenes | 1 | 2010 | 37 | 0.340 |
Why?
| | Eye Diseases | 2 | 2020 | 92 | 0.340 |
Why?
| | Prospective Studies | 11 | 2025 | 7739 | 0.340 |
Why?
| | Young Adult | 17 | 2025 | 13673 | 0.330 |
Why?
| | Nerve Regeneration | 1 | 2010 | 59 | 0.330 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 38 | 0.320 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 601 | 0.320 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 20 | 0.310 |
Why?
| | Immune System Phenomena | 1 | 2009 | 3 | 0.310 |
Why?
| | Meningioma | 2 | 2023 | 95 | 0.310 |
Why?
| | Virus Diseases | 1 | 2011 | 215 | 0.300 |
Why?
| | Rats | 12 | 2021 | 5629 | 0.300 |
Why?
| | Adolescent | 18 | 2024 | 22007 | 0.300 |
Why?
| | Cell Survival | 2 | 2019 | 1129 | 0.300 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 2158 | 0.290 |
Why?
| | Nervous System Diseases | 2 | 2020 | 275 | 0.290 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 113 | 0.280 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 128 | 0.280 |
Why?
| | Neurology | 2 | 2007 | 111 | 0.280 |
Why?
| | Ophthalmology | 2 | 2007 | 105 | 0.270 |
Why?
| | Protein Binding | 7 | 2025 | 2239 | 0.270 |
Why?
| | Antibodies | 3 | 2017 | 409 | 0.270 |
Why?
| | Cerebral Cortex | 3 | 2023 | 461 | 0.270 |
Why?
| | Peptide Library | 5 | 2025 | 95 | 0.260 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 140 | 0.260 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 20 | 0.260 |
Why?
| | Immunization, Passive | 3 | 2020 | 90 | 0.260 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 49 | 0.250 |
Why?
| | T-Lymphocytes | 3 | 2023 | 2002 | 0.250 |
Why?
| | Mutation | 6 | 2019 | 4013 | 0.250 |
Why?
| | Corpus Callosum | 1 | 2006 | 70 | 0.250 |
Why?
| | Transcriptome | 4 | 2020 | 1003 | 0.250 |
Why?
| | Antibody Formation | 1 | 2007 | 298 | 0.250 |
Why?
| | Gyrus Cinguli | 2 | 2024 | 94 | 0.250 |
Why?
| | Proteomics | 2 | 2012 | 1134 | 0.240 |
Why?
| | Herpes Zoster | 3 | 2015 | 319 | 0.240 |
Why?
| | Atrophy | 2 | 2023 | 193 | 0.240 |
Why?
| | B-Lymphocyte Subsets | 2 | 2024 | 77 | 0.230 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 27 | 0.230 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2025 | 57 | 0.230 |
Why?
| | Syndecan-1 | 4 | 2011 | 41 | 0.230 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2025 | 245 | 0.230 |
Why?
| | Retrospective Studies | 12 | 2026 | 16273 | 0.230 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 23 | 0.230 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 179 | 0.230 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2025 | 68 | 0.220 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 11 | 0.220 |
Why?
| | Acute Disease | 3 | 2018 | 1008 | 0.220 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 46 | 0.210 |
Why?
| | Spastic Paraplegia, Hereditary | 1 | 2024 | 12 | 0.210 |
Why?
| | Cerebellar Ataxia | 1 | 2024 | 13 | 0.210 |
Why?
| | Touch Perception | 1 | 2024 | 19 | 0.210 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 62 | 0.210 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 28 | 0.210 |
Why?
| | Consciousness | 1 | 2024 | 31 | 0.210 |
Why?
| | Nystagmus, Pathologic | 1 | 2024 | 16 | 0.210 |
Why?
| | Blindness, Cortical | 1 | 2003 | 6 | 0.210 |
Why?
| | Diagnosis, Differential | 6 | 2023 | 1498 | 0.210 |
Why?
| | Risk Assessment | 4 | 2021 | 3490 | 0.210 |
Why?
| | Proteoglycans | 1 | 2004 | 109 | 0.210 |
Why?
| | Proteolipids | 1 | 2023 | 29 | 0.210 |
Why?
| | Paraplegia | 1 | 2024 | 61 | 0.210 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 184 | 0.200 |
Why?
| | Epitope Mapping | 4 | 2017 | 61 | 0.200 |
Why?
| | Seroconversion | 1 | 2023 | 46 | 0.200 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 854 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 147 | 0.200 |
Why?
| | Neuroprotection | 1 | 2023 | 43 | 0.200 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2023 | 234 | 0.200 |
Why?
| | Immune System | 1 | 2004 | 183 | 0.200 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 148 | 0.190 |
Why?
| | Cells, Cultured | 7 | 2016 | 4208 | 0.190 |
Why?
| | Vision Disorders | 2 | 2021 | 157 | 0.190 |
Why?
| | Incidence | 3 | 2025 | 2794 | 0.190 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2929 | 0.190 |
Why?
| | Zika Virus | 1 | 2023 | 128 | 0.180 |
Why?
| | Hippocampus | 2 | 2021 | 939 | 0.180 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2180 | 0.180 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1764 | 0.180 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 433 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 573 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 501 | 0.180 |
Why?
| | Antibody Affinity | 2 | 2019 | 60 | 0.180 |
Why?
| | Protein Isoforms | 4 | 2017 | 398 | 0.180 |
Why?
| | Zika Virus Infection | 1 | 2023 | 165 | 0.170 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 202 | 0.170 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 29 | 0.170 |
Why?
| | Comorbidity | 2 | 2024 | 1662 | 0.170 |
Why?
| | Internationality | 2 | 2019 | 158 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 34 | 0.170 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1150 | 0.170 |
Why?
| | Schizophrenia | 2 | 2022 | 454 | 0.170 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 51 | 0.170 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 46 | 0.160 |
Why?
| | Animals, Newborn | 3 | 2018 | 863 | 0.160 |
Why?
| | Azathioprine | 1 | 2020 | 50 | 0.160 |
Why?
| | Cell Proliferation | 3 | 2020 | 2504 | 0.160 |
Why?
| | Visual Pathways | 3 | 2023 | 59 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 792 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 772 | 0.160 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 36 | 0.160 |
Why?
| | Myelin Proteins | 2 | 2017 | 45 | 0.160 |
Why?
| | Amygdala | 1 | 2021 | 192 | 0.160 |
Why?
| | Viral Vaccines | 1 | 2020 | 107 | 0.160 |
Why?
| | Cell Separation | 2 | 2015 | 317 | 0.150 |
Why?
| | Prevalence | 2 | 2024 | 2772 | 0.150 |
Why?
| | Steroids | 1 | 2020 | 163 | 0.150 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 15 | 0.150 |
Why?
| | United States | 3 | 2025 | 15220 | 0.150 |
Why?
| | Models, Molecular | 3 | 2025 | 1603 | 0.150 |
Why?
| | Child | 13 | 2024 | 22308 | 0.150 |
Why?
| | Treatment Outcome | 11 | 2024 | 11120 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 60 | 0.150 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 10 | 0.150 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 7 | 0.150 |
Why?
| | Cell Lineage | 1 | 2020 | 350 | 0.150 |
Why?
| | Oxidoreductases | 1 | 2019 | 96 | 0.150 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 469 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 161 | 0.140 |
Why?
| | Neurogenesis | 3 | 2016 | 154 | 0.140 |
Why?
| | Peptides | 2 | 2019 | 978 | 0.140 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 60 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 403 | 0.140 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 81 | 0.140 |
Why?
| | Point Mutation | 1 | 2019 | 237 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 63 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 276 | 0.130 |
Why?
| | Spatial Analysis | 1 | 2017 | 21 | 0.130 |
Why?
| | Skull Neoplasms | 1 | 2017 | 21 | 0.130 |
Why?
| | Sphenoid Bone | 1 | 2017 | 17 | 0.130 |
Why?
| | Mice, Knockout | 9 | 2017 | 3068 | 0.130 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 78 | 0.130 |
Why?
| | Cohort Studies | 5 | 2022 | 5799 | 0.130 |
Why?
| | Antibodies, Viral | 4 | 2023 | 653 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 546 | 0.130 |
Why?
| | Orbital Diseases | 1 | 2017 | 34 | 0.130 |
Why?
| | Albumins | 1 | 2017 | 115 | 0.130 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 108 | 0.130 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 368 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 918 | 0.120 |
Why?
| | Microvessels | 1 | 2017 | 86 | 0.120 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 75 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5200 | 0.120 |
Why?
| | Fibrinogen | 1 | 2017 | 180 | 0.120 |
Why?
| | Interferon-beta | 2 | 2025 | 93 | 0.120 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 324 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2020 | 792 | 0.120 |
Why?
| | HEK293 Cells | 4 | 2022 | 737 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 501 | 0.120 |
Why?
| | Ethics, Research | 1 | 2015 | 34 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 662 | 0.120 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 6 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 354 | 0.120 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 9 | 0.120 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 417 | 0.120 |
Why?
| | Retinal Neurons | 1 | 2015 | 3 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.120 |
Why?
| | Aged, 80 and over | 8 | 2021 | 7856 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 371 | 0.110 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 246 | 0.110 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.110 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 2 | 0.110 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 78 | 0.110 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 859 | 0.110 |
Why?
| | Plasma Exchange | 1 | 2014 | 18 | 0.110 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3776 | 0.110 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 98 | 0.110 |
Why?
| | Nerve Fibers | 1 | 2015 | 100 | 0.110 |
Why?
| | Alanine | 1 | 2015 | 153 | 0.110 |
Why?
| | Nuclear Proteins | 1 | 2019 | 712 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 987 | 0.110 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 269 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2064 | 0.110 |
Why?
| | Glycine | 1 | 2015 | 182 | 0.100 |
Why?
| | Erythropoietin | 1 | 2014 | 98 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2013 | 19 | 0.100 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.100 |
Why?
| | Fetal Death | 1 | 2013 | 60 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2520 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| | Antibody Specificity | 2 | 2011 | 187 | 0.100 |
Why?
| | Neurons | 5 | 2024 | 1619 | 0.100 |
Why?
| | Autism Spectrum Disorder | 2 | 2016 | 412 | 0.100 |
Why?
| | Biomedical Research | 1 | 2019 | 703 | 0.100 |
Why?
| | Syndrome | 2 | 2019 | 378 | 0.090 |
Why?
| | Proteome | 2 | 2015 | 483 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2166 | 0.090 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 82 | 0.090 |
Why?
| | Phenotype | 3 | 2020 | 3166 | 0.090 |
Why?
| | Computer Simulation | 1 | 2017 | 1015 | 0.090 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 169 | 0.090 |
Why?
| | Exanthema | 1 | 2013 | 81 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 672 | 0.090 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 47 | 0.090 |
Why?
| | Antigens, CD20 | 2 | 2023 | 35 | 0.090 |
Why?
| | Area Postrema | 1 | 2011 | 2 | 0.090 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 6 | 0.090 |
Why?
| | Cranial Sinuses | 1 | 2011 | 14 | 0.090 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 15 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 147 | 0.090 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 32 | 0.090 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 112 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1653 | 0.090 |
Why?
| | Fundus Oculi | 1 | 2011 | 86 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2017 | 816 | 0.090 |
Why?
| | Cerebral Angiography | 2 | 2011 | 114 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2015 | 739 | 0.090 |
Why?
| | Quality of Life | 1 | 2023 | 2999 | 0.090 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 82 | 0.090 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 175 | 0.080 |
Why?
| | Brain Mapping | 2 | 2024 | 532 | 0.080 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 8 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2013 | 244 | 0.080 |
Why?
| | Risk Factors | 4 | 2016 | 10438 | 0.080 |
Why?
| | Cell Line | 3 | 2011 | 2885 | 0.080 |
Why?
| | Spinal Puncture | 1 | 2009 | 20 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4073 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 208 | 0.080 |
Why?
| | Pregnancy | 5 | 2023 | 7070 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1763 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 1143 | 0.080 |
Why?
| | Genes | 1 | 2009 | 229 | 0.070 |
Why?
| | Databases, Factual | 1 | 2015 | 1444 | 0.070 |
Why?
| | Brain Injuries | 1 | 2014 | 502 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 6956 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 48 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 625 | 0.070 |
Why?
| | Clone Cells | 3 | 2017 | 266 | 0.070 |
Why?
| | Optic Disk | 1 | 2008 | 52 | 0.070 |
Why?
| | Transfection | 3 | 2018 | 943 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3588 | 0.070 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 30 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 528 | 0.070 |
Why?
| | Pregnancy Complications | 1 | 2013 | 587 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 17 | 0.070 |
Why?
| | Vision, Low | 1 | 2007 | 17 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 532 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 285 | 0.070 |
Why?
| | Molecular Biology | 2 | 2009 | 60 | 0.070 |
Why?
| | Health | 1 | 2007 | 84 | 0.070 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.070 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 6 | 0.070 |
Why?
| | Visual Fields | 1 | 2007 | 115 | 0.070 |
Why?
| | Measles virus | 1 | 2006 | 20 | 0.070 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 27 | 0.060 |
Why?
| | Bevacizumab | 1 | 2007 | 139 | 0.060 |
Why?
| | Puerperal Disorders | 1 | 2007 | 33 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 106 | 0.060 |
Why?
| | Vitreous Body | 1 | 2007 | 122 | 0.060 |
Why?
| | Binding, Competitive | 2 | 2019 | 196 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 38 | 0.060 |
Why?
| | Models, Immunological | 1 | 2006 | 101 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 230 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5636 | 0.060 |
Why?
| | Injections, Spinal | 2 | 2016 | 108 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2007 | 360 | 0.060 |
Why?
| | Spatio-Temporal Analysis | 2 | 2016 | 34 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1154 | 0.060 |
Why?
| | Myelography | 1 | 2025 | 37 | 0.060 |
Why?
| | Fetus | 1 | 2009 | 802 | 0.060 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2025 | 59 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1444 | 0.060 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.060 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3469 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 550 | 0.060 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 51 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 278 | 0.050 |
Why?
| | Child, Preschool | 4 | 2021 | 11457 | 0.050 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 20 | 0.050 |
Why?
| | Risk | 1 | 2007 | 904 | 0.050 |
Why?
| | Touch | 1 | 2024 | 37 | 0.050 |
Why?
| | Fistula | 1 | 2024 | 47 | 0.050 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 42 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2025 | 193 | 0.050 |
Why?
| | Granzymes | 1 | 2024 | 50 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2746 | 0.050 |
Why?
| | Ataxia | 1 | 2024 | 70 | 0.050 |
Why?
| | Somatosensory Cortex | 1 | 2024 | 42 | 0.050 |
Why?
| | Patient Selection | 1 | 2008 | 688 | 0.050 |
Why?
| | Geniculate Bodies | 1 | 2023 | 20 | 0.050 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2024 | 63 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2363 | 0.050 |
Why?
| | Receptors, IgG | 1 | 2023 | 77 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 226 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2902 | 0.050 |
Why?
| | Optic Nerve Neoplasms | 1 | 2023 | 11 | 0.050 |
Why?
| | Headache | 1 | 2024 | 148 | 0.050 |
Why?
| | Eye Abnormalities | 1 | 2002 | 17 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 93 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1081 | 0.050 |
Why?
| | Developmental Biology | 1 | 2002 | 23 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 67 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 157 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2006 | 1018 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 40 | 0.050 |
Why?
| | Antigens, Surface | 1 | 2022 | 156 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2793 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2015 | 313 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 103 | 0.050 |
Why?
| | Eye | 1 | 2002 | 113 | 0.050 |
Why?
| | Primates | 1 | 2022 | 140 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 386 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1316 | 0.040 |
Why?
| | Glycoproteins | 1 | 2023 | 356 | 0.040 |
Why?
| | Delphi Technique | 1 | 2023 | 308 | 0.040 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 40 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 310 | 0.040 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 8 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3292 | 0.040 |
Why?
| | Base Sequence | 1 | 2004 | 2180 | 0.040 |
Why?
| | COS Cells | 2 | 2011 | 183 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 367 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1973 | 0.040 |
Why?
| | Aging | 2 | 2024 | 1892 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 490 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 117 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 704 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 309 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 101 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 14 | 0.040 |
Why?
| | Serum | 1 | 2019 | 60 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 740 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2015 | 874 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2021 | 299 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 204 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1828 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 166 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 47 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 908 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2016 | 1487 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1319 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 298 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2009 | 363 | 0.030 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 19 | 0.030 |
Why?
| | Clonal Deletion | 1 | 2017 | 16 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 27 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 21 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 678 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3348 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 168 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1320 | 0.030 |
Why?
| | Craniotomy | 1 | 2017 | 81 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 225 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 150 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 136 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2017 | 106 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 5 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 194 | 0.030 |
Why?
| | Neocortex | 1 | 2016 | 44 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1816 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2016 | 238 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 107 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 855 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 551 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 100 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 509 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 386 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 369 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 309 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 583 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 424 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 50 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 468 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 44 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 525 | 0.030 |
Why?
| | Intellectual Disability | 1 | 2016 | 172 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 368 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 250 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 20 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 10 | 0.030 |
Why?
| | SOXC Transcription Factors | 1 | 2013 | 5 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 41 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 63 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 22 | 0.030 |
Why?
| | Neurodevelopmental Disorders | 1 | 2016 | 196 | 0.030 |
Why?
| | Narcolepsy | 1 | 2013 | 25 | 0.020 |
Why?
| | Multigene Family | 1 | 2013 | 202 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 4 | 0.020 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 28 | 0.020 |
Why?
| | Parkinson Disease | 1 | 2019 | 569 | 0.020 |
Why?
| | Interneurons | 1 | 2013 | 124 | 0.020 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 265 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 720 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 464 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 196 | 0.020 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 111 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 88 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 42 | 0.020 |
Why?
| | Phlebography | 1 | 2011 | 37 | 0.020 |
Why?
| | O Antigens | 1 | 2011 | 9 | 0.020 |
Why?
| | Vaccination | 1 | 2020 | 1467 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 202 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 209 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2892 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 309 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 579 | 0.020 |
Why?
| | Genome | 1 | 2013 | 302 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 56 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 330 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 667 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 132 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 157 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 236 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 146 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 216 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1052 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1820 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 131 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 42 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 37 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2255 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 747 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1737 | 0.020 |
Why?
| | Water | 1 | 2012 | 464 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 443 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 168 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 157 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 252 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 343 | 0.020 |
Why?
| | Virion | 1 | 2009 | 113 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 242 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 811 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 464 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 366 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 583 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1274 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1110 | 0.020 |
Why?
| | Glioma | 1 | 2010 | 427 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 771 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2098 | 0.010 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 9 | 0.010 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 13 | 0.010 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 12 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1431 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1187 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 824 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 750 | 0.010 |
Why?
| | Infant | 1 | 2017 | 9818 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2599 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 661 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1556 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1597 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 5144 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 5929 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|